---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-007988"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:30:51.261407+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aprea reports first partial response for APR-1051; raises $5.6M in private placement

## Summary
- First unconfirmed partial response (uPR) in PPP2R1A-mutated endometrial cancer at 150 mg: 50% target lesion reduction, CA-125 from 732 to 70 U/mL.
- Stable disease at 70 mg (HNSCC, 5% reduction) and 100 mg (colon cancer, 15% reduction; >210 days on therapy).
- Private placement ~$5.6M gross: 6.3M shares/pre-funded warrants + 6.3M warrants at $0.765; priced $0.89/unit. Closes Jan 30, 2026.
- Dose escalation continues; 220 mg cohort enrolling; company plans to increase HPV-positive enrollment.
- Potential dose-response trend observed across 70 mg, 100 mg, and 150 mg cohorts.

## SEC filing metadata
- accession: 0001104659-26-007988
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/0001104659-26-007988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/tm264417d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-007988
- JSON: https://secwatch.observer/filing/0001104659-26-007988.json
- Plain text: https://secwatch.observer/filing/0001104659-26-007988.txt

## Key facts
- Material Agreements
  Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors (the Purchasers) valued at expected aggregate gross proceeds at closing of approximately $5.6 million (effective 2026-01-28).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors (the Purchasers)
  - Value: expected aggregate gross proceeds at closing of approximately $5.6 million
  - Effective: 2026-01-28
  source text: On January 28, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 6,288,857 shares (the “ Private Placement Shares ”) of the Company’s Common Stock, par value $0.001 per share (“ Common Stock ”) or pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) in lieu thereof, and (ii) common stock purchase warrants to purchase up to 6,288,857 shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.765 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/0001104659-26-007988-index.htm
- Material Agreements
  Aprea Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Purchasers valued at customary indemnification rights (effective 2026-01-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Company and the Purchasers
  - Value: customary indemnification rights
  - Effective: 2026-01-29
  source text: In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated January 29, 2026 (the “ Registration Rights Agreement ”), providing for the registration for resale of Private Placement Shares along with the shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants that are not then registered on an effective registration statement, pursuant to a registration statement (the “ Registration Statement ”) to be filed with the Securities and Exchange Commission (the “ SEC ”) on or prior to the 60 th day after the Closing Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/0001104659-26-007988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.